Moderna Halts Development of Birth Defect Vaccine After Trial Setback

Moderna halts development of birth defect vaccine after trial setback

Moderna said on Wednesday it would discontinue development of its experimental vaccine to prevent cytomegalovirus after it failed to meet the goal of a trial.

Moderna drops after reporting trial for birth defect vaccine failed

In statements announcing the results, Moderna’s leaders described the results at “disappointing.”...

Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint

Moderna’s investigational cytomegalovirus (CMV) vaccine, mRNA-1647, did not meet its primary endpoint in a Phase 3 trial, leading the company to discontinue its congenital CMV program while continuing studies in transplant patients.